Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crenigacestat in Japanese patients with advanced solid tumors
NCT02836600Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2016
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of crenigacestat in solid tumor (advanced stage) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants With LY3039478 Dose-Limiting Toxicities. Started Sep 2016; status: completed.
02
Drugs
crenigacestat
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02836600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02836600.